67 Bricks CEO, Jennifer Schivas, has been named as one of EQL:Her‘s 2025 InspiringFifty.

Fable Therapeutics, a discovery-stage biotechnology company developing purpose-built biologics powered by state-of-the-art structure and sequence-based protein language models, today announced the ...

The novel selective antibody sibeprenlimab reduced proteinuria more than any prior drug for IgA nephropathy, with excellent ...

Adding an SGLT2 inhibitor to finerenone in CKD and type 2 diabetes yields “remarkable” albuminuria reductions that may, if ...

Pascal Soriot, Chief Executive Officer, AstraZeneca, said ... leveraging our two large R&D sites in Gaithersburg MD and Cambridge MA. Overall, we are making excellent progress toward our ambition ...

AstraZeneca is bolstering its US manufacturing ... leveraging our two large R&D sites in Gaithersburg MD and Cambridge MA.’ Soriot also told reporters the drugmaker will maintain its 2025 ...

AstraZeneca has 11 production sites in the U.S. covering small molecules, biologics as well as cell therapy. It also has two large R&D sites in Gaithersburg MD and Cambridge MA.” Guidance ...

"Additionally, we have even greater US investment in manufacturing and R&D planned, leveraging our two large R&D sites in Gaithersburg MD and Cambridge MA. "Overall, we are making excellent progress ...

Additionally, we have even greater US investment in manufacturing and R&D planned, leveraging our two large R&D sites in Gaithersburg MD and Cambridge MA. Overall, we are making excellent progress ...

Additionally, we have even greater US investment in manufacturing and R&D planned, leveraging our two large R&D sites in Gaithersburg MD and Cambridge MA. Overall ... eleven US manufacturing sites.